LOBEF (Lobe Sciences) Other Current Liabilities: $0.14 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOBEF Lobe Sciences Ltd LOBEF
16 GF Score
Price $0.08
! 2 Warning Signs
View Full Analysis

What is Lobe Sciences Other Current Liabilities?

Lobe Sciences LOBEF -2.44% 16 Other Current Liabilities is $0.14 Mil as of Feb. 2026. GuruFocus rates LOBEF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Lobe Sciences's other current liabilities for the quarter that ended in Feb. 2026 was $0.14 Mil.

Lobe Sciences's quarterly other current liabilities declined from Aug. 2025 ($0.15 Mil) to Nov. 2025 ($0.10 Mil) but then increased from Nov. 2025 ($0.10 Mil) to Feb. 2026 ($0.14 Mil).

Lobe Sciences's annual other current liabilities increased from Aug. 2023 ($-0.00 Mil) to Aug. 2024 ($0.44 Mil) but then declined from Aug. 2024 ($0.44 Mil) to Aug. 2025 ($0.15 Mil).

Lobe Sciences Other Current Liabilities Related Terms

Lobe Sciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Other Current Liabilities Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.44 0.15

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.37 0.15 0.10 0.14
LOBEF
16GF Score
Lobe Sciences Ltd LOBEF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lobe Sciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.14 Mil mean?
Lobe Sciences (LOBEF) has a Other Current Liabilities of $0.14 Mil as of Feb. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lobe Sciences.
Is Lobe Sciences' Other Current Liabilities too high?
Lobe Sciences' current Other Current Liabilities is $0.14 Mil. Overall, Lobe Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Lobe Sciences' Other Current Liabilities compare to VRTX and REGN?
Lobe Sciences' Other Current Liabilities of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lobe Sciences. Lobe Sciences's current Other Current Liabilities is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Other Current Liabilities of $0.14 Mil. The current Other Current Liabilities is $0.14 Mil. Lobe Sciences' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Other Current Liabilities is $0.14 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.
16GF Score

Get the complete analysis for LOBEF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price